Luxi Products

Company's existing 34 product number, more than 100 quality regulation, annual production capacity tablets 2 billion tablets, 200 million capsules, external lotion 50 million bottles, 2.5 tons of raw materials. The main product products are...

Custom Synthesis

A marketing mix tailored to individual needs to meet the specific needs of each customer. The modern custom marketing differs from the previous handwork custom, the custom marketing is in the simple large-scale production cannot satisfy the ...

Shandong Luxi Pharmaceutical Co., Ltd. was established on June 27, 1991, is a modern pharmaceutical enterprise integrating R&D, production and sales of APIs and preparations. The company registered capital is 31.88 million yuan, state assets of 100 million yuan, and a cumulative investment of 150 million yuan. The company has more than 170 employees and covers an area of more than 100,000 square meters. All the workshops have passed GMP certification issued by the State Medical Products Administration. The company has biological engineering, API, pharmaceutical preparations three business units. It has a total of 34 product numbers and more than 100 product specifications, with an annual production capacity of 2 billion tablets, 200 million capsules, 150 million bottles of external lotions and 500 tons of APIs. Among them, the leading active substances such as brasspiperate hydrochloride and polymyxin sulfate all rank the top in China, and it has established long-term strategic cooperative relations with many well-known multinational enterprises such as Johnson & Johnson, Berigo and Boehringer Ingelheim. It has a national epidemic prevention reserve of medical materials, povidone iodine solution. "Luxi" brand was rated as "famous brand in Shandong Province" by "Shandong Administration for Industry and Commerce".